Explosion in Psoriasis Drug Development Promising
February 4, 2011|Dermatology News
Author and Disclosure Information
EXPERT ANALYSIS FROM THE LAS VEGAS DERMATOLOGY SEMINAR SPONSORED BY SDEF
"Whether or not these are going to be significant, we'll have to wait and see," Dr. Leonardi said. "At least it showed some promise."
SDEF and this news organization are owned by Elsevier.
Dr. Leonardi declared having potential conflicts of interest with Pfizer (which is developing tasocitinib), Celgene (apremilast), Abbott (briakinumab and adalimumab), Centocor (ustekinumab, infliximab, and golimumab), Amgen (etanercept), Abgenix, Allergan, Alza, Biogen-IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Connetics, Corixa, Fujisawa, Galderma, Genentech, Genzyme, GSK, Incyte, Isis, Lilly, MedImmune, Miravant, Schering Plough, Serono, Synta, Wyeth, and Xoma.
